Ultra-Rare Disease Approvals By US FDA Could Take More ‘Mechanistic,’ Less ‘Empirical’ Approach

Acting Commissioner Woodcock says ‘we weren’t as flexible as we should be’ and notes that center directors are reviewing the criteria for rare disease assessments.